Please note, many of our Member Awards have been created throughout our nearly 20-year history. As a result, some lists date back farther than others. In addition, you may notice that names and titles reflect information we had on file at the time of the award and may not be current.
2023 - Casey B. Williams, PharmD MBA BCOP FHOPA
2020-22 - Not Awarded
2019 - George Carro, RPh MS BCOP
2018 - R. Donald Harvey, PharmD BCOP FCCP FHOPA
2017 - Terri G. Davidson, PharmD BCCP BCOP FASHP
2016 - Niesha L. Griffith, MS RPh FASHP
2015 - David W. Henry, MS BCOP FASHP
2014 - Rowena N. Schwartz, PharmD BCOP
2013 - Robert Ignoffo, PharmD FASHP FCSHP
2012 - Susan Goodin, PharmD
2011 - Jim Koeller, MS
2010 - Val R. Adams, PharmD FCCP BCOP
2009 - Barry R. Goldspiel, PharmD BCOP BCPS FASHP FISOPP
2008 - Carol M. Balmer, PharmD BCOP
2007 - Jane M. Pruemer, PharmD BCOP FASHP
2006 - Judy L. Chase, PharmD FASHP
2006 - Amy W. Valley, PharmD BCOP
2005 - LeAnne D. Kennedy, BCOP
2023 - Zanette Kanani Bradley, PharmD BCOP
2023 - Mya Merrow, PharmD BCOP
2022 - Maurice Alexander, PharmD, BCOP
2022 - Britny R. Brown, PharmD, BCOP
2023 - Sarah Cimino, PharmD BCOP
2022 - Kathryn Maples, PharmD BCOP
2021 - Justin Arnall, PharmD BCOP
2020 - Kirollos S. Hanna, PharmD BCPS BCOP
2020 - Megan N. Dillaman, PharmD, BCOP
2019 - Megan May, PharmD BCOP
2018 - Alexandra Shillingburg, PharmD BCOP
2017 - Amber Bradley Clemmons, PharmD BCOP
2016 - Kristin Held Wheatley, PharmD BCOP
2015 - Patrick J. Kiel, PharmD BCPS BCOP
2014 - Robert S. Mancini, PharmD BCOP
2013 - Steve Stricker, PharmD MS BCOP
2012 - Daniel Zlott, PharmD BCOP
2011 - Trevor McKibbin, PharmD MS BCPS
2010 - LeAnn Best Norris, PharmD BCPS BCOP
2009 - Julianna Burzynski, PharmD BCPS BCOP
2008 - Janet Espirito, PharmD BCOP
2023 - Allison Kane, PharmD
2022 - Sarah E. Wheeler, PharmD, BCOP
2021 - Megan Langer, PharmD, BCOP
2020 - Kathy Hogan Edwards, PharmD, BCPS, BCOP
2019 - Ashley Glode, PharmD BCOP
2018 - Not Awarded
2017 - Kerry Parsons, PharmD BCOP FHOPA
2016 - Benyam Muluneh, PharmD BCOP CPP
2015 - Rowena N. Schwartz, PharmD BCOP
2014 - Sarah S. Hudson-DiSalle, PharmD RPh
2023 - Tabitha Sowers Alvarado, AA CPhT
2022 - Alicia M. Holguin, CPhT & May Lo
2021 - Emily Zimdars, BA, CPhT
2021 - Jessica Turner, CPhT
2020- Alexamil Rodriguez, CPhT
2019 - Amanda Pate, CPhT
2018- Desiree Rolniak, CPhT
2017 - Cheryl Hyk, MA CPhT
2016 - Edward D. Gormley, BS CPhT
2012-2015 - Not Awarded
2011 - Tanja Monroe
2010 - Therese McGrain, CPhT
2009 - Jeanne Anderson, CPhT
2008 - Kenneth Grohgans, CPhT
2007 - Darrell Clarke, CPhT
2007 - Anne Hameed, CPhT
2023 - C. Brooke Adams, PharmD BCOP
2022 - Mallika P. Patel, PharmD, CPP
2020 - Eve-Michell Segal, PharmD, BCOP
2021 - Not Awarded
2019 - Ila Saunders, PharmD BCOP
2023 - Robert S. Mancini, PharmD, BCOP, FHOPA
2022 - Not Awarded
2021 - Ali McBride, PharmD, MS
2023 - Jonathan Cohen, PharmD, BCOP, Lee C, Markham R, Szerwo J, Roska M, Bubalo J. Medication use process and assessment of extemporaneous compounding and alternative routes of administration of oral oncology drugs: Guidance for clinical and oncology pharmacists. J Am Coll Clin Pharm. 2022;1-53. DOI: 10.1002/jac5.1698
2022 - Shannon Hough, PharmD, BCOP, Hough S, McDevitt R, Nachar VR, Kraft S, Brown A, Christen C, Frame D, Smerage JB. Chemotherapy Remote Care Monitoring Program: Integration of SMS Text Patient-Reported Outcomes in the Electronic Health Record and Pharmacist Intervention for Chemotherapy-Induced Nausea and Vomiting. JCO Oncol Pract. 2021 Feb 3:OP2000639. doi: 10.1200/OP.20.00639
2021 - Grant Lee, PharmD, Lee GW, Mathur AD, Andrick BJ, Leese E, Zally D, Gatson NTN. Pharmacist value-added to neuro-oncology subspecialty clinics: a pilot study uncovers opportunities for best practices and optimal time utilization. J Oncol Pharm Pract. 2020 Sep 17;1078155220957738. PubMed PMID: 32938297.
2020 - Jacqueline L. Olin, M.S., PharmD, BCPS, Olin JL, Klibanov O, Chan A, Spooner LM. Managing pharmacotherapy in people living with HIV and concomitant malignancy. Ann Pharmacother 2019 Aug;53(8):812-832. doi: 10.1177/1060028019833038. Epub 2019 Feb 15.
2019 - Julianne Orr, PharmD BCOP, Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, Deremer D. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Biology of Blood and Marrow Transplantation. 2018;24(10):2065–71.
2018 - NA
2017 - Karen Sweiss, PharmD, Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant 2016; e-pub ahead of print 16 May 2016; doi:10.1038/bmt.2016.136.
2016 - Ginah Nightingale, PharmD BCOP, Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33:1453-1459.
2015 - Joseph S. Bubalo, PharmD BCOP BCPS, Bubalo J, Carpenter PA, Majhail N, Perales MA, Marks DI, Shaughnessy P, Pidala J, Leather HL, Wingard J, Savani BN. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014 May;20(5):600-16. doi:10.1016/j.bbmt.2014.01.019. Epub 2014 Jan 23.
2014 - Ali McBride, PharmD MS BCPS BCOP, McBride A, Lathon S, Boehmer L, Augustin KM, Butler SK, Westervelt P. Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome. Pharmacotherapy. 2013;33(3):295-303.
2013 - Kamakshi V. Rao, PharmD BCOP CPP, Strother RM, Rao KV, Gregory KM, Jakait B, Busakhala N, Schellhase E, Pastakia S, Krzyzanowski M, Loehrer PJ. The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya. J Oncol Pharm Pract 2012. Jan 16
2012 - Kristine R. Crews, PharmD, BCPS, Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 68:143-50, 2011
2011 - NA
2010 - Brian Crandell, PharmD, BCOP, O'Bryant CL, Crandell BC. Community pharmacists’ knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc. 2008;48:632-9.
2023 - Aaron W. Stewart, PharmD, CTTS, Shillingburg A, Petros W, Wen S, Piktel D, Moses R, Gibson LF, Craig M, Cumpston A. A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with non-obese controls. Pharmacotherapy. 2022 Jan;42(1):53-57. doi: 10.1002/phar.2646. Epub 2021 Nov 22. PMID: 34767652.
2022 - Lydia Benitez, PharmD, BCOP Benitez, LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffin S, Olson M, Crain M, Kadia T, Pettit K, Burke PW, Bixby DL, Marini BL. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378. Epub ahead of print. PMID: 33830856.
2021 - Victoria Nachar, PharmD, BCOP, Hoylman E, Brown A, Perissinotti A, et al. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2020 Mar;61(3):691-698
2020 -Daniel J. Crona, PharmD, PhD, CPP, Crona DJ, Skol AD, Leppänen V-M, Glubb DM, Etheridge AS, Hilliard E, Peña C, Peterson Y, Klauber-DeMore N, Alitalo KK, Innocenti F. Novel genetic determinants of survival in renal cell carcinoma patients treated with sorafenib: a clinical and translational experimental study. Cancer Res. 2019 Jan; 79(1):231-241. PMCID: PMC6541205.
2019 - Judith A. Smith, BS PharmD BCOP CPHQ FCCP FISOPP, Cotton S, Brown RE, Nugent EK, Robazetti SC, Berens PD, Smith JA. Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women With Latent Human Papillomavirus Infections. Obstetrics & Gynecology. 2018Apr;131(4):681–7.
2018 - NA
2017 - NA
2016 - Meghana V. Trivedi, PharmD PhD BCOP, Do T, Medhekar R, Bhat R, Chen H, Niravath P, Trivedi MV. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2015 Oct;153(3):591-7. Epub 2015 Sep 4.
2015 - David J. Reeves, PharmD BCOP, Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014 Sep;78(3):565-71. Doi: 10.1111/bcp.12384 PMID: 24646036
2014 -Casey B. Williams, PharmD BCOP, Williams CB, Kambhampati S, Fiskus W, Wick J, Dutreix C, Ganguly S, Aljitawi O, Reyes R, Fleming A, Abhyankar S, Bhalla KN, McGuirk JP. Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia. Pharmacotherapy. 2013 Jun 24. doi: 10.1002/phar.1316.
2013 - Wendelin Nelson, PharmD BCOP, Nelson WK, Formica RN, Cooper DL, Schwartz PE, Rutherford TJ. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. J Oncol Pharm Pract 2012;18(3):323-332.
2012 - Cindy O'Bryant, PharmD BCOP FCCP, O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol. 2011 Sep 22
2011 - Jacob K. Kettle, PharmD, Kettle JK, Grauer D, Folker TL, et al. Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy. Pharmacotherapy. 2010;30(8):812-817.
2010 - LeAnne Kennedy, PharmD, BCOP, Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion. 2008;48:2285-91.
2009 - Stacy S. Shord, PharmD, BCOP, Sandra Cuellar, PharmD, BCOP, Shord SS, Hamilton JM Jr, Cuellar S. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia. J Oncol Pharm Pract. 2008;14:5-22.
2007 - Donald A. Hutcherson, RPh Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy. 2006;26:242-247.
2006 - Susan Goodin, PharmD, BCOP, Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55:117-142
2007 - Dominic A. Solimando Jr, MA, RPh, BCOP, FAPhA, FASHP
2006 - David Baribeault, RPh, BCOP and Sachin Shah, PharmD, BCOP
